These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31602234)

  • 1. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis.
    Hu JH; Chang ML; Liu NJ; Yeh CT; Huang TJ
    Exp Ther Med; 2019 Nov; 18(5):3568-3578. PubMed ID: 31602234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
    Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
    Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
    Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    Gut Liver; 2009 Jun; 3(2):108-15. PubMed ID: 20431732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
    Deltenre P; Louvet A; Lemoine M; Mourad A; Fartoux L; Moreno C; Henrion J; Mathurin P; Serfaty L
    J Hepatol; 2011 Dec; 55(6):1187-94. PubMed ID: 21703195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
    J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
    Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
    Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of hepatitis c virus infection status with serum glucose levels.
    Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
    BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
    Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.
    Cacoub P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Pol S; Halfon P
    Antivir Ther; 2009; 14(6):839-45. PubMed ID: 19812446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
    J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Elhelbawy M; Abdel-Razek W; Alsebaey A; Hashim M; Elshenawy H; Waked I
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):16-23. PubMed ID: 30024489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
    Khattab MA; Eslam M; Shatat M; Abd-Aalhalim H; Mousa YI; Samir F; Aly H; Shaker O; Shaker Y
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):59-65. PubMed ID: 22457861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
    J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
    Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
    Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus.
    Todorovska B; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Popova-Jovanovska R; Grivceva-Stardelova K; Licoska-Josifovic F; Andreevski V; Curakova-Ristovska E; Joksimovic N
    Open Access Maced J Med Sci; 2019 May; 7(10):1641-1648. PubMed ID: 31210815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.